Effects of Fetal Exposure to Maternal Chemotherapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Approximately 1 in 1,000–2,000 pregnancies are complicated by cancer. Today, different treatment options are considered as safe during pregnancy: chemotherapy, radiotherapy, surgery, or a combination of these. Surgery is considered safe during all trimesters of pregnancy; radiotherapy can be administered during the first and the second trimester, and chemotherapy after the first trimester of pregnancy. The placenta, acting as a barrier between the mother and the fetus, plays a key role in the safe administration of chemotherapy during pregnancy. A few studies have investigated the short- as well as the long-term health, general development, and cognitive and cardiac outcomes on children exposed to chemotherapy in utero. In general, these results were reassuring. Nevertheless, better safety data are required. This means data with longer follow-up periods and comparison with appropriate control groups. Moreover, important biasing factors should be taken into account when interpreting these results. Firstly, a great proportion of children were born prematurely due to the maternal condition. Preterm birth in general has been associated with cognitive impairment. Secondly, cancer during pregnancy is clearly a stressful situation, and maternal stress is associated with attention deficits. In sum, we state that chemotherapy can be administered safely after the first trimester of pregnancy. Moreover, iatrogenic prematurity in order to start postpartum administration of chemotherapy should be avoided. Nonetheless, decisions concerning treatment in these specific cases should always be made in a multidisciplinary setting with internationally recognized expertise in the coexistence of cancer and pregnancy.
- Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7(4):279–87.
- Walton JR, Prasad MR. Obstetric and neonatal outcomes of cancer treated during pregnancy. Clin Obstet Gynecol. 2011;54(4):567–73. CrossRef
- Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28(4):683–9. CrossRef
- Luis SA, Christie DR, Kaminski A, et al. Pregnancy and radiotherapy: management options for minimising risk, case series and comprehensive literature review. J Med Imaging Radiat Oncol. 2009;53(6):559–68. CrossRef
- Van Calsteren K, Verbesselt R, Beijnen J, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol. 2010;119(3):594–600. CrossRef
- Arnon J, Meirow D, Lewis-Roness H, et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update. 2001;7(4):394–403. CrossRef
- Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283–91. CrossRef
- Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997;74(2):207–20. CrossRef
- De Santis M, Di Gianantoni E, Straface G, et al. Ionizing radiations in pregnancy and teratogenesis: a review of literature. Reprod Toxicol. 2005;20(3):323–9. CrossRef
- Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005;6(5):328–33. CrossRef
- Amant F, Van Calsteren K, Halaska MJ, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer. 2009;19(Suppl 1):S1–12. CrossRef
- Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy: case report and literature review. Gynecol Oncol. 2001;80(3):405–8. CrossRef
- Amant F, Loibl S, Neven P, et al. Breast cancer in pregnancy. Lancet. 2012;379(9815):570–9. CrossRef
- Rasmussen SA. Human teratogens update 2011: can we ensure safety during pregnancy? Birth Defects Res A Clin Mol Teratol. 2012;94(3):123–8. CrossRef
- Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6(6):821–6. CrossRef
- Azim HA Jr, Metzger-Filho O, de Azambuja E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 2012;133(1):387–91. CrossRef
- Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs. 2011;71(15):1973–87. CrossRef
- Decker M, Rothermundt C, Hollander G, et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol. 2006;7(8):693–4. CrossRef
- Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–506. CrossRef
- Shapira T, Pereg D, Lishner M. How I treat acute and chronic leukemia in pregnancy. Blood Rev. 2008;22(5):247–59. CrossRef
- Vandenbriele C, Vassou A, Pentheroudakis G, et al. Hematologic malignancies in pregnancy. In: Antica M, editor. Acute leukemia: the scientist’s perspective and challenge. New York: InTech; 2011. p. 371–90.
- Eskander RN, Tarsa M, Herbst KD, et al. Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. J Obstet Gynaecol Res. 2011;37(11):1731–3. CrossRef
- Yazdani BP, Matok I, Garcia BF, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33(3):265–8. CrossRef
- Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta. 2006;27(8):861–8. CrossRef
- Garland M. Pharmacology of drug transfer across the placenta. Obstet Gynecol Clin N Am. 1998;25(1):21–42. CrossRef
- Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43(8):487–514. CrossRef
- Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol. 2006;22(3):400–10. CrossRef
- Gaillard B, Leng JJ, Grellet J, et al. Transplacental passage of epirubicin [article in French]. J Gynecol Obstet Biol Reprod (Paris). 1995;24(1):63–8.
- Grohard P, Akbaraly JP, Saux MC, et al. Transplacental passage of doxorubicin [article in French]. J Gynecol Obstet Biol Reprod (Paris). 1989;18(5):595–600.
- Heyns L, Van Calsteren K, Han SN, et al. Review: chemotherapy during pregnancy. Belgian J Hematol. 2011;2(3):101–6.
- Van Calsteren K, Verbesselt R, Van Bree R, et al. Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model. Reprod Sci. 2011;18(1):57–63. CrossRef
- Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971–94.
- Van Calsteren K, Verbesselt R, Ottevanger N, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand. 2010;89(10):1338–45. CrossRef
- Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med. 2007;357(12):1190–8. CrossRef
- Avilés A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2(3):173–7. CrossRef
- Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107(6):1219–26. CrossRef
- Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;9:256–64. CrossRef
- Voigt B, Pietz J, Pauen S, et al. Cognitive development in very vs. moderately to late preterm and full-term children: can effortful control account for group differences in toddlerhood? Early Hum Dev. 2012;88(5):307–13. CrossRef
- van Baar AL, Vermaas J, Knots E, et al. Functioning at school age of moderately preterm children born at 32 to 36 weeks’ gestational age. Pediatrics. 2009;124(1):251–7. CrossRef
- Mulder EJ, Robles de Medina PG, Huizink AC, et al. Prenatal maternal stress: effects on pregnancy and the (unborn) child. Early Hum Dev. 2002;70(1–2):3–14. CrossRef
- Van den Bergh BR, Mennes M, Stevens V, et al. ADHD deficit as measured in adolescent boys with a continuous performance task is related to antenatal maternal anxiety. Pediatr Res. 2006;59(1):78–82. CrossRef
- Effects of Fetal Exposure to Maternal Chemotherapy
Volume 15, Issue 5 , pp 329-334
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Author Affiliations
- 1. Lab of Experimental Gynaecology, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium
- 2. Obstetrics, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium
- 3. Gynaecologic Oncology, University Hospitals Leuven, Katholieke Universiteit Leuven, Herestraat 49, Leuven, 3000, Belgium